Neurodevelopmental Outcomes Following Bevacizumab Injections for Retinopathy of Prematurity

Abstract

Preterm infants treated with bevacizumab versus laser had higher odds of severe neurodevelopmental disabilities. Further investigation on the long-term safety of antivascular endothelial growth factor treatment of ROP is needed.